Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,728.50
Bid: 1,727.00
Ask: 1,728.00
Change: 0.00 (0.00%)
Spread: 1.00 (0.058%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 1-Chief executives and the itch to quit

Thu, 16th May 2013 10:28

By Andrew Callus

LONDON, May 16 (Reuters) - On approaching his 60th birthdaythis year, long-serving Tullow Oil boss Aidan Heaveytold staff he felt "like two 30 year-olds".

A handful of recent shock departures by 50-something chiefexecutives at European blue chip companies - none of them underany obvious pressure to quit - suggest some of his peers eitherlack that vigour, or want to channel it elsewhere.

Peter Voser is giving up one of the world's most challengingCEO roles at Royal Dutch/Shell next year, before his55th birthday, in pursuit of a "lifestyle change".

Swiss engineering group ABB's 55-year old boss Joe Hogan is also going, for "private reasons". Pierre-OlivierBeckers, 53, is walking out on Belgian retailer Delhaize, and Paul Walsh, 57, is waving goodbye to drinksmultinational Diageo.

All four are about average European CEO age.

Luxury goods group Richemont's chairman and founderJohann Rupert, older, at 62, than the rest of the May retirees,gave up the CEO post in April and on Thursday announced he wouldtake a year off from the chairmanship, too, to catch up on somereading. And perhaps a trip to the Antarctic.

While the rising financial rewards of running a modernmultinational have been well publicised, executive recruiterssay the pressures of the job have also been ratcheted up inrecent years, and not just because of the tough economic times.

"The reality is it's gruelling. It's really tough, and therecomes a point where you don't want to do it any more," said IanButcher, who headhunts board-level and senior executives for MWMConsulting.

"The quarterly reporting, the governance, the regulatoryaspects, it just becomes very wearing - the level of scrutiny,the pace at which things are moving, the short-term nature ofhow people look at any given situation. Even over the past fiveyears these things have made CEO a tougher position to hold, andthe travel that people have to undertake in these jobs - it'sjust something they run out of steam on."

"I just want to be master of my time for some time," saidRichemont's Rupert.

Some recent early retirees, while still well short oftraditional retirement age, got to the top spot early.

"They're still in their early fifties, with energy and adesire to do something, but they want to do something different,something quite significantly different sometimes," saysButcher.

Voser might not be donning snow shoes for an Antarcticventure, but he has no plans to collect well-paid chairmanshipsand non-executive directorships, as many ex-CEOs have done inthe past. Former Tesco chief Terry Leahy has alsoresisted that gravy train since he left two years ago.

As for the early starters, executive search industryprofessionals point at people like Andrew Witty, the CEO ofGlaxoSmithKline, who took on the job aged 44 in 2008 andwould have to stay in harness for another decade to reach 60 inthe role.

Blue-chip bosses as young as Witty are still rare, but overa quarter of Europe's current crop have less than two years inthe job, and more than half have less than four, according todata from executive search specialists BoardEx.

MEDIAN CEO AGE IS 55 YEARS

The BoardEx data, collected for Reuters from 238 companiesin the main stock indexes of Germany, Britain, France, Spain,Italy, Belgium, the Netherlands and Denmark, puts the median CEOage at 55, and the median tenure at four years. Only 16 percentof the group have held on for 10 years and more. ()

The longest serving of them is Martin Gilbert of the Britishfund Aberdeen Asset Management. Though younger, at 57,Gilbert pips the 28.3-year tenure of Tullow's double thirtyyear-old Heavey, with 29.8 years at the helm.

There are 17 top European CEOs who have been in the job forless than six months, and the youngest of the 225 in the groupfor whom ages were available is Vitaly Nesis, 37, who runsPolymetal International, the London-listed Russianprecious metals miner.

While the recent spate of quitters are looking for somethingelse to do, there are still some who appear to want nothing but.

In the BoardEx group there are four over 70, and the oldestby eight years is Albert Frere, CEO of Group Bruxelles Lambert.

Perhaps some linger on for fear that the pension pot isstill a little light. Frere will have put such qualms behind himlong ago. At 87, he is Belgium's richest man.

More News
17 Dec 2023 15:16

PRESS: GSK looks for deals in China as rebuilds relationship

(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.

Read more
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:24

GSK seeks to extend RSV vaccine approval in Japan

(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.

Read more
11 Dec 2023 08:28

GSK drug gets EU marketing backing for form of endometrial cancer

(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more
11 Dec 2023 07:23

GSK endometrial cancer treatment gets Europe authorisation

(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.

Read more
7 Dec 2023 12:54

THG backer Kelso pushes for demerger to trim "inherent" valuation gap

(Alliance News) - THG PLC investor Kelso Group Holdings PLC on Thursday reiterated its call for a demerger, which the shareholder believes will help close the "disparity" between the e-commerce firm's share price and its true value.

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
27 Nov 2023 09:00

GSK announces positive results from Blenrep phase 3 blood cancer trial

(Alliance News) - GSK PLC on Monday said a phase 3 trial of belantamab mafodotin as a multiple myeloma treatment has produced positive headline results.

Read more
27 Nov 2023 08:02

GSK receives 'positive' headline results from phase III trial

(Sharecast News) - Drugmaker GSK announced on Monday that it had received positive headline results from a planned interim efficacy analysis from a phase III trial evaluating its elantamab mafodotin asset.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.